-
Featured Authors
-
Archives
- September 2016
- August 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- November 2015
- October 2015
- September 2015
- August 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Tag Archives: AMP v. Myriad Genetics
IP Sessions at BIO 2015: The Evolving Landscape of Patentable Subject Matter
The IP Track at BIO 2015 had a number of incredible educational sessions concerning the most relevant topics in the biotech sector. Let’s look back at what top experts in the IP field had to say about the changing nature of patentable subject matter: Panelists included: Jennifer Swan and Howard Levine, Finnegan, Henderson, Farabow, Garrett & Dunner, LLP Raul Tamayo, USPTO P. Michael Walker, E.I. du Pont de Nemours and Company Panelists focused on the increasingly restrictive interpretation of patent eligibility, Read More >
Patently BIOtech
Leave a comment
Email This Post
Tags: 2015 BIO International Convention, 35 U.S.C. § 101, Akamai v. Limelight, AMP v. Myriad Genetics, Ariosa, Ariosa v. Sequenom, BIO 2015, Diamond v. Diehr, federal circuit, highlights, Intellectual Property, Interim Eligibility Guidance, IP, Mayo, Mayo v. Prometheus, patent, patent claim, patentable subject matter, Section 101, subject matter eligibility, USPTO, USPTO Subject Matter Eligibility Guidance
Tags: 2015 BIO International Convention, 35 U.S.C. § 101, Akamai v. Limelight, AMP v. Myriad Genetics, Ariosa, Ariosa v. Sequenom, BIO 2015, Diamond v. Diehr, federal circuit, highlights, Intellectual Property, Interim Eligibility Guidance, IP, Mayo, Mayo v. Prometheus, patent, patent claim, patentable subject matter, Section 101, subject matter eligibility, USPTO, USPTO Subject Matter Eligibility Guidance
BIO and University Organizations offer Support of STRONG Patents Act
On March 4, 2015, Senator Chris Coons (D-DE) introduced a new bill, The STRONG Patents Act of 2015. Sponsored alongside Sen. Richard Durbin (D-IL) and Sen. Mazie Hirono (D-HI), the bill is offered as a complement to House Judiciary Committee Chairman Goodlatte’s (R-VA) Innovation Act, which many in the biotech sector see as an imbalanced bill. The STRONG Patents Act of 2015 would target the abusive practices of patent trolls in a narrowly tailored setting, Read More >
Patently BIOtech
Leave a comment
Email This Post
Tags: AAU, AMP v. Myriad, AMP v. Myriad Genetics, APLU, Association of American Universities, Association of Public and Land Grant Universities, BIO IPCC, biopharma, biotech IP, Biotech Patent, Biotech Patenting, Chris Coons, claims construction, House Innovation Act, ineligible claim, Intellectual Property, inter partes review, IP, IPCC, Mayo, Mayo v. Prometheus, Mayo v. Prometheus and Myriad v. AMP, Myriad, patent, patent application, patent claim, patent licensing, Patent Reform, Senator Coons, Strong Patents Act, The Myriad Case
Tags: AAU, AMP v. Myriad, AMP v. Myriad Genetics, APLU, Association of American Universities, Association of Public and Land Grant Universities, BIO IPCC, biopharma, biotech IP, Biotech Patent, Biotech Patenting, Chris Coons, claims construction, House Innovation Act, ineligible claim, Intellectual Property, inter partes review, IP, IPCC, Mayo, Mayo v. Prometheus, Mayo v. Prometheus and Myriad v. AMP, Myriad, patent, patent application, patent claim, patent licensing, Patent Reform, Senator Coons, Strong Patents Act, The Myriad Case
BIO IPCC Spring Conference Program Announced
BIO’s 2015 IP Counsels Committee Spring Conference & Meeting will be held April 15-17 in St. Louis, Missouri, at the Four Seasons St. Louis Hotel. The biannual conference offers timely, relevant educational sessions on the latest issues in the biotech IP sector, informal networking events designed to promote discussion and foster relationships among industry colleagues, and practical tips for attendees to use the next day. Attendees will hear from the foremost experts in biotech IP Read More >
Patently BIOtech
Leave a comment
Email This Post
Tags: AIA, American Investment Act, AMP v. Myriad, AMP v. Myriad Genetics, BIO IPCC, biopharma, biotech IP, Biotech Patent, Biotech Patenting, claims construction, ineligible claim, Intellectual Property, inter partes review, IP, IPCC, Mayo, Mayo v. Prometheus, Mayo v. Prometheus and Myriad v. AMP, Myriad, patent, patent application, patent claim, patent licensing, Patent Reform, The Myriad Case
Tags: AIA, American Investment Act, AMP v. Myriad, AMP v. Myriad Genetics, BIO IPCC, biopharma, biotech IP, Biotech Patent, Biotech Patenting, claims construction, ineligible claim, Intellectual Property, inter partes review, IP, IPCC, Mayo, Mayo v. Prometheus, Mayo v. Prometheus and Myriad v. AMP, Myriad, patent, patent application, patent claim, patent licensing, Patent Reform, The Myriad Case
BIO Deputy General Counsel Remarks on Revised Eligibility Guidance
Hans Sauer, BIO’s Deputy General Counsel for Intellectual Property recently spoke at the U.S. Patent and Trademark Office’s public forum on patent-eligible subject matter. The forum was a chance for the Office to receive public feedback regarding the most recently revised Eligibility Guidance for determining subject matter under 35 U.S.C. 1010. Biotechnology advocates are concerned that PTO examiners have interpreted recent decisions by the U.S. Supreme Court, including those in Alice Corp, Myriad, and Mayo Read More >
Patently BIOtech
Leave a comment
Email This Post
Tags: Alice, Alice v. CLS Bank, AMP v. Myriad Genetics, Biotech Patent, Biotech Patenting, federal patent applications, Mayo, Mayo v. Prometheus, Mayo v. Prometheus and Myriad v. AMP, Myriad, patent, Patent and Trademark Office, patent application, patent applications, patent cases, patent protection, PTO, subject matter eligibility, U.S. Patent and Trademark Office, USPTO, USPTO Guidance
Tags: Alice, Alice v. CLS Bank, AMP v. Myriad Genetics, Biotech Patent, Biotech Patenting, federal patent applications, Mayo, Mayo v. Prometheus, Mayo v. Prometheus and Myriad v. AMP, Myriad, patent, Patent and Trademark Office, patent application, patent applications, patent cases, patent protection, PTO, subject matter eligibility, U.S. Patent and Trademark Office, USPTO, USPTO Guidance
USPTO Issues New Myriad Guidance
On Tuesday, December 16 the United States Patent and Trademark Office issued a revised guidance on subject matter eligibility under § 101 in light of recent Supreme Court Decisions in Alice v. CLS Bank, Mayo, and Myriad. These new guidelines are a response to extensive feedback provided from industry leaders and inventors over the last several months. (BIO provided both initial and supplemental comments on the Office’s March Subject Matter Eligibility Guidance). Public comments on the Read More >
Patently BIOtech
Leave a comment
Email This Post
Tags: Alice, Alice v. CLS Bank, AMP v. Myriad Genetics, biotechnology patent, Mayo, Mayo v. Prometheus, Myriad, patent, patent claim, patent law, patent litigation, Patent Reform, product of nature, subject matter eligibility, United States Patent and Trademark Office, USPTO
Tags: Alice, Alice v. CLS Bank, AMP v. Myriad Genetics, biotechnology patent, Mayo, Mayo v. Prometheus, Myriad, patent, patent claim, patent law, patent litigation, Patent Reform, product of nature, subject matter eligibility, United States Patent and Trademark Office, USPTO
